Prelude Capital Management’s Novavax NVAX Stock Holding History

Prelude Capital Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-400	Closed	-$5K	–	2176
2020 Q1	$5K	Buy	+400	New	+$3.38K	﹤0.01%	1229

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Prelude Capital Management's NVAX Position: Q2 2025 in Review

Prelude Capital Management sold out of Novavax (NVAX) in Q2 2025, closing a stake of 19,213 shares — an estimated $123K sold.

Prelude Capital Management first reported a position in NVAX in Q3 2015 and held it in 3 quarters. The position peaked at $123K in Q1 2025. 251 funds tracked by Wall St. Rank hold NVAX as of Q2 2025.

Prelude Capital Management reported no remaining Novavax position as of Q2 2025 after selling out during the quarter.
Prelude Capital Management sold 19,213 Novavax shares in Q2 2025, an estimated $123K.
Prelude Capital Management first reported a position in Novavax in Q3 2015 and held it in 3 quarters.
Prelude Capital Management's Novavax position peaked at $123K in Q1 2025.
251 funds tracked by Wall St. Rank held Novavax as of Q2 2025.

Based on Prelude Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.